Comparative Pharmacology
Head-to-head clinical analysis: LODINE XL versus ONMEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LODINE XL versus ONMEL.
LODINE XL vs ONMEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis leading to anti-inflammatory, analgesic, and antipyretic effects.
ONMEL (omacetaxine mepesuccinate) inhibits protein synthesis by binding to the 80S ribosome and interfering with chain elongation, leading to apoptosis in leukemic cells.
400 mg or 600 mg orally once daily.
50 mg orally twice daily for 14 days
None Documented
None Documented
Terminal elimination half-life is approximately 6-7 hours. Steady-state is achieved within 2 days.
Terminal half-life 40–60 hours (mean 50 hours); allows once-daily dosing for systemic antifungal therapy.
Renal excretion of metabolites accounts for approximately 70% of a dose; fecal excretion accounts for about 20%.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; >90% eliminated as metabolites in bile and feces.
Category C
Category C
NSAID
NSAID